必赢电子

 
 
Yuling Qiu, Associate Professor
发布人:药必赢电子-英文  发布时间:2019-12-05   浏览次数:143

 

Yuling Qiu, Ph.D.

 

 


Yuling Qiu, PhD

Associate Professor

Department of Pharmacy

Tianjin Medical  University

22 Qixiangtai Road

Tianjin 3000070

Phone: +86-22-83336659

Email: qiuyuling@tmu.edu.cn

 

Education

MD     Shenyang Pharmaceutical University, Shenyang, Liaoning, China, 2006

Ph.D.  Dong-A University, Busan, Republic of Korea, 2009

 

Professional Experience

2018-          Associate Professor, Department of Pharmacy, Tianjin Medical University, Tianjin, China

2012-2017  Assistant Professor, Department of Pharmacy, Tianjin Medical University, Tianjin, China

 

Honors

 

 

Professional Service

 

Membership of Academic Society

Chinese Pharmaceutical Society (CNPHARS)

Chinese Anti-Cancer Association (CACA) Committee of Anti-Cancer Agent

 

Publication

(1)   Hongwei Liu#, Qian Chen#, Di Lu#, Xu Pang, Shuangshuang Yin, Kailong Wang, Rui Wang, Shenshen Yang, Yi Zhang, Yuling Qiu*, Tao Wang*, Haiyang Yu*. HTBPI, an active phenanthroindolizidine alkaloid, inhibits liver tumorigenesis by targeting Akt. FASEB Journal. 2020; 34(9): 12255-12268. (Co-correspondence author)

(2)   Yiman Liu#, Shenshen Yang#, Kailong Wang, Jia Lu, Xiaomei Bao, Rui Wang, Yuling Qiu*, Tao Wang*, Haiyang Yu*. Cellular senescence and cancer: Focusing on traditional Chinese medicine and natural products. Cell Proliferation. 2020; 53(10): e12894. (Co-correspondence author)

(3)   Lei Zhang#, Ting Chen#, Yonghai Dou, Shaolu Zhang, Hongyan Liu, Tungalagtamir Khishignyam, Xiaofei Li, Duo Zuo, Zhe Zhang, Meihua Jin, Ran Wang, Yuling Qiu*, Yuxu Zhong*, DexinKong*. Atorvastatin exerts antileukemia activity via inhibiting mevalonate-YAP axis in K562 and HL60 cells. Frontiers in oncology. 2019; 9:1032. (Co-correspondence author)

(4)   Shuangshuang Yin#, Yuling Qiu#, Chengyun Jin#, Rui Wang, Song Wu, Hongwei Liu, Sangho Koo, Lifeng Han, Yi Zhang, Xiumei Gao, Xu Pang*, Tao Wang*, Haiyang Yu*. 7-Deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma. Internal journal of Cancer. 2019; 145(12):3334-3346. (Co-first author)

(5)   Song Wu#, Yuling Qiu#, Yingying Shao, Shuangshuang Yin, Rui Wang, Xu Pang, Junhong Ma, Chunze Zhang, Bo Wu, Sangho Koo, Lifeng Han, Yi Zhang, Xiumei Gao, Tao Wang*, Haiyang Yu*. Lycorine displays potent antitumor efficacy in colon carcinoma by targeting STAT3. Frontiers in Pharmacology. 2018; 9:881.(Co-first author)

(6)   Haiyang Yu, Shuangshuang Yin, Shiyue Zhou, Yingying Shao, Jiachen Sun, Xu Pang, Lifeng Han, Yi Zhang, Xiumei Gao, Chengyun Jin*, Yuling Qiu*, Tao Wang*. Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/ Mcl-1 axis in human colorectal cancers. Cell Death and Disease. 2018; 9:702.(Co-correspondence author)

(7)   Lei Zhang, Zhengming Wang, Tungalagtamir Khishignyam Ting Chen, Chang Zhou, Zhe Zhang, Meihua Jin, Ran Wang, Yuling Qiu*, Dexin Kong*. In vitro anti- leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ ADR and K562/A02 cells.Biomedicine and Pharmacotherapy. 2018; 103:1069-1078. (Co-correspondence author)

(8)   Wennan Zhao#, Yuling Qiu#, Dexin Kong*. Class I phosphatidy- linositol 3-kinase inhibitors for cancer therapy. Acta Pharmaceutica Sinica B. 2017; 7:27-37. (Co-first author)

(9)   Qianxiang Zhou, Yali Chen, Xi Chen, Wennan Zhao, Yuxu Zhong, Ran Wang, Meihua Jin, Yuling Qiu*, Dexin Kong*. In vitro anti- leukemia activity of ZSTK474 on K562 and multidrug resistant K562/A02 cells. International Journal of Biological Sciences. 2016; 12:631-638. (Co-correspondence author)

(10)Yali Chen, Qianxiang Zhou, Lei Zhang, Ran Wang, Meihua Jin, Yuling Qiu*, Dexin Kong*. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells. Oncology Reports. 2016; 36:3643-3650. (Co-correspondence author)                       

 

Grant